Effects of low and high dose administration of bis(maltolato)oxovanadium(IV) on fa/fa Zucker rats.

The fatty Zucker rat, characterized by obesity, hyperinsulinemia, hyperlipidemia, and mild hyperglycemia, has been suggested as an animal model of non-insulin-dependent diabetes mellitus. The present study examined the chronic dose-dependent effect of bis(maltolato)oxovanadium(IV), a potent insulin mimetic, in this animal model of diabetes. Chronic (6 weeks) oral administration of bis(maltolato)oxovanadium(IV) (0.06 mmol.kg-1.day-1, low dose study) was effective in reducing the hyperinsulinemia associated with the fatty Zucker rat model (termination insulin: lean, 82.8 +/- 21.6; fatty, 732 +/- 89.4; fatty treated, 336 +/- 126.6 pmol/L; p < 0.05). Pancreatic perfusion data indicated a significant improvement in insulin secretory function in the fatty rats. The dose dependency of this relationship was observed in the high dose study (0.128 mmol.kg-1.day-1 for 14 weeks), wherein bis(maltolato)oxovanadium(IV) treatment restored plasma insulin levels in the fatty rats to lean levels (termination insulin: lean, 199.2 +/- 17.4; fatty 660.6 +/- 12.6; fatty treated, 153.6 +/- 9.6 pmol/L; p < 0.05) and significantly improved insulin response to a glucose challenge. In addition, bis(maltolato)oxovanadium(IV) treatment (high dose study) ameliorated the age-dependent increase in blood pressure observed in fatty Zucker rats (systolic blood pressure: lean, 127 +/- 10; fatty, 176 +/- 5; fatty treated, 156 +/- 9 mmHg (1 mmHg = 133.3 Pa)). These data indicate that chronic oral administration of bis(maltolato)oxovanadium(IV) in the drinking water was effective in reducing hyperinsulinemia, insulin resistance, glucose intolerance, and hypertension in the fatty Zucker rat.

[1]  C. Kahn,et al.  Metabolic effects of sodium metavanadate in humans with insulin-dependent and noninsulin-dependent diabetes mellitus in vivo and in vitro studies. , 1995, The Journal of clinical endocrinology and metabolism.

[2]  H. Shamoon,et al.  Oral vanadyl sulfate improves hepatic and peripheral insulin sensitivity in patients with non-insulin-dependent diabetes mellitus. , 1995, The Journal of clinical investigation.

[3]  S. Bhanot,et al.  Antihypertensive effects of metformin in fructose-fed hyperinsulinemic, hypertensive rats. , 1994, The Journal of pharmacology and experimental therapeutics.

[4]  S. Bhanot,et al.  Vanadyl sulfate lowers plasma insulin and blood pressure in spontaneously hypertensive rats. , 1994, Hypertension.

[5]  N. Paquot,et al.  How to measure insulin action in vivo. , 1994, Diabetes/metabolism reviews.

[6]  J. McNeill,et al.  Integrated cardiovascular function in the conscious streptozotocin-diabetic deoxycorticosterone-acetate-hypertensive rats. , 1994, Pharmacology.

[7]  S. Bhanot,et al.  Vanadyl sulfate prevents fructose-induced hyperinsulinemia and hypertension in rats. , 1994, Hypertension.

[8]  C. Bailey,et al.  Islet defects and insulin resistance in models of obese non-insulin-dependent diabetes. , 1993, Diabetes/metabolism reviews.

[9]  J. Sowers,et al.  Insulin attenuation of vasopressin-induced calcium responses in arterial smooth muscle from Zucker rats. , 1993, Endocrinology.

[10]  M. Novelli,et al.  Beneficial effects of the oral administration of vanadyl sulphate on glucose metabolism in senescent rats. , 1993, Journal of gerontology.

[11]  J. McNeill,et al.  Improvement in cardiac dysfunction in streptozotocin-induced diabetic rats following chronic oral administration of bis(maltolato)oxovanadium(IV). , 1993, Canadian journal of physiology and pharmacology.

[12]  J. McNeill,et al.  Glucose-lowering effects of a new organic vanadium complex, bis(maltolato)oxovanadium(IV). , 1993, Canadian journal of physiology and pharmacology.

[13]  J. McNeill,et al.  Myocardial performance of STZ-diabetic DOCA-hypertensive rats. , 1992, The American journal of physiology.

[14]  J. McNeill,et al.  Effects of deoxycorticosterone acetate on glucose metabolism in nondiabetic and streptozotocin-diabetic rats. , 1992, Canadian Journal of Physiology and Pharmacology.

[15]  E. Shafrir,et al.  Animal models of non-insulin-dependent diabetes. , 1992, Diabetes/metabolism reviews.

[16]  J. Sredy,et al.  Metabolic abnormalities of the hyperglycemic obese Zucker rat. , 1992, Metabolism: clinical and experimental.

[17]  A. Hebden,et al.  Measurement of cardiac left ventricular pressure in conscious rats using a fluid-filled catheter. , 1992, Journal of pharmacological and toxicological methods.

[18]  J. McNeill,et al.  Bis(maltolato)oxovanadium(IV) is a potent insulin mimic. , 1992, Journal of medicinal chemistry.

[19]  M. Zemel,et al.  Hypertension in insulin-resistant Zucker obese rats is independent of sympathetic neural support. , 1992, The American journal of physiology.

[20]  M. Zemel,et al.  Mechanisms of hypertension in diabetes. , 1991, American journal of hypertension.

[21]  M. Zemel,et al.  Insulin attenuates vasopressin-induced calcium transients and a voltage-dependent calcium response in rat vascular smooth muscle cells. , 1991, The Journal of clinical investigation.

[22]  O. Madsen,et al.  Lifelong sequential changes in glucose tolerance and insulin secretion in genetically obese Zucker rats (fa/fa) fed a diabetogenic diet. , 1991, Endocrinology.

[23]  S. Brichard,et al.  Marked Improvement of Glucose Homeostasis in Diabetic ob/ob Mice Given Oral Vanadate , 1990, Diabetes.

[24]  L. Rossetti,et al.  Insulinomimetic Properties of Trace Elements and Characterization of Their In Vivo Mode of Action , 1990, Diabetes.

[25]  H. Imura,et al.  Importance of Impaired Insulin-Gene Expression in Occurrence of Diabetes in Obese Rats , 1990, Diabetes.

[26]  P. Weidmann,et al.  Insulin, insulin sensitivity and hypertension. , 1990, Journal of hypertension.

[27]  L. Slieker,et al.  Effect of Streptozocin-Induced Diabetes on Insulin-Receptor Tyrosine Kinase Activity in Obese Zucker Rats , 1990, Diabetes.

[28]  J. McNeill,et al.  Enhanced in vivo sensitivity of vanadyl-treated diabetic rats to insulin. , 1990, Canadian journal of physiology and pharmacology.

[29]  Y. Shechter.  Insulin-Mimetic Effects of Vanadate: Possible Implications for Future Treatment of Diabetes , 1990, Diabetes.

[30]  R. Pederson,et al.  Long-Term Effects of Vanadyl Treatment on Streptozocin-Induced Diabetes in Rats , 1989, Diabetes.

[31]  S. Brichard,et al.  Long term improvement of glucose homeostasis by vanadate in obese hyperinsulinemic fa/fa rats. , 1989, Endocrinology.

[32]  J. McNeill,et al.  Oral vanadyl sulfate in treatment of diabetes mellitus in rats. , 1989, The American journal of physiology.

[33]  T. Kurtz,et al.  The Zucker Fatty Rat as a Genetic Model of Obesity and Hypertension , 1989, Hypertension.

[34]  S. Brichard,et al.  Long term improvement of glucose homeostasis by vanadate treatment in diabetic rats. , 1988, Endocrinology.

[35]  R. Withers,et al.  Glucose transport: locus of muscle insulin resistance in obese Zucker rats. , 1988, The American journal of physiology.

[36]  G. Reaven,et al.  A ROLE FOR INSULIN IN THE AETIOLOGY AND COURSE OF HYPERTENSION? , 1987, The Lancet.

[37]  B. Rodrigues,et al.  Cardiac function in spontaneously hypertensive diabetic rats. , 1986, The American journal of physiology.

[38]  G. Reaven,et al.  Insulin and blood pressure in obesity. , 1985, Hypertension.

[39]  J. Stern,et al.  Dynamics of insulin hypersecretion by obese Zucker rats. , 1985, Metabolism: clinical and experimental.

[40]  B. Jeanrenaud,et al.  Abnormal oral glucose tolerance in genetically obese (fa/fa) rats. , 1985, The American journal of physiology.

[41]  J. McNeill,et al.  Effect of vanadate on elevated blood glucose and depressed cardiac performance of diabetic rats. , 1985, Science.

[42]  J. Brown,et al.  Gastric Inhibitory Polypeptide (GIP) and Insulin Release in the Obese Zucker Rat , 1984, Diabetes.

[43]  J. Brown,et al.  Effect of jejunoileal bypass in the rat on the enteroinsular axis , 1982, Regulatory Peptides.

[44]  E. Planche,et al.  Onset and development of hypertriglyceridemia in the Zucker rat (fa/fa). , 1981, Metabolism: clinical and experimental.

[45]  V. Herbert,et al.  Coated charcoal immunoassay of insulin. , 1965, The Journal of clinical endocrinology and metabolism.

[46]  L. Zucker.  HEREDITARY OBESITY IN THE RAT ASSOCIATED WITH HYPERLIPEMIA * , 1965, Annals of the New York Academy of Sciences.

[47]  Henry Wl.  Perspectives in diabetes. , 1962 .

[48]  T. Zucker,et al.  FATTY, A NEW MUTATION IN THE RAT , 1961 .

[49]  J. McNeill,et al.  Comparison of the glucose-lowering properties of vanadyl sulfate and bis(maltolato)oxovanadium(IV) following acute and chronic administration. , 1995, Canadian journal of physiology and pharmacology.

[50]  G. Fink,et al.  Obese Zucker rats are normotensive on normal and increased sodium intake. , 1992, Hypertension.

[51]  B. Kasiske,et al.  The Zucker rat model of obesity, insulin resistance, hyperlipidemia, and renal injury. , 1992, Hypertension.

[52]  A. G. Tahiliani,et al.  Cardiovascular abnormalities associated with human and rodent obesity. , 1992, Life sciences.